FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2089349496> ?p ?o ?g. }

• W2089349496 endingPage "629" @default.
• W2089349496 startingPage "623" @default.
• W2089349496 abstract "Over-expression of epidermal growth factor receptor (EGFR) has been observed in a variety of epithelial tumours. The selective inhibition of the associated signalling pathway using monoclonal antibodies appears to be a promising therapeutic target. Individual differences in response rates, particularly against highly selective chemotherapeutic agents, underline the need for further research of the molecular basis of this process. Previously described resistance mechanisms are not able to explain all refractory responses. Several subgroups of the melanoma-associated antigens (MAGE) tumour antigens were described in connection with regulatory functions relating to the cell cycle and chemosensitivity. In the present study, five cell lines of human squamous cell carcinomas were treated with cetuximab and panitumumab (0.01–100 μg/ml) over a period of 24 or 48 h. The efficacy of the agents used was measured dynamically using real-time cell analysis (RTCA). Subsequently, the expression levels of MAGE-A1, -A5, -A8, -A9, -A11 and -A12 were determined by RT-qPCR. A correlation between chemosensitivity and MAGE-A expression was investigated. The tumour cell lines exhibited a very low overall response to the chemotherapy drugs. Only one cell line showed a cytostatic effect after treatment with cetuximab and panitumumab. This effect, however, was significant only for panitumumab. The expression of MAGE-A12 was significantly associated with greater efficacy of panitumumab. The expression of MAGE-A5 and -A8 was associated with poorer response rates after panitumumab treatment. Due to an insignificant effect of cetuximab on the number of viable cells, no correlation with the MAGE-A levels was observed. For the first time, these results show a correlation between the efficacies of EGFR inhibitors and various MAGE-A subgroups in the treatment of HNSCC. Determining the MAGE-A status could help to improve the success of anti-tumour drug therapy. In addition, evaluating MAGE-A levels might be an important tool in the development of patient-specific treatment protocols." @default.
• W2089349496 created "2016-06-24" @default.
• W2089349496 creator A5001616605 @default.
• W2089349496 creator A5010774833 @default.
• W2089349496 creator A5030811057 @default.
• W2089349496 creator A5035703944 @default.
• W2089349496 creator A5057080440 @default.
• W2089349496 creator A5060991124 @default.
• W2089349496 creator A5063577202 @default.
• W2089349496 creator A5063605118 @default.
• W2089349496 creator A5090518514 @default.
• W2089349496 date "2013-10-01" @default.
• W2089349496 modified "2023-09-28" @default.
• W2089349496 title "Efficacy of cetuximab and panitumumab in oral squamous cell carcinoma cell lines: Prognostic value of MAGE-A subgroups for treatment success" @default.
• W2089349496 cites W1971251456 @default.
• W2089349496 cites W1973401399 @default.
• W2089349496 cites W1979479754 @default.
• W2089349496 cites W1984622518 @default.
• W2089349496 cites W2003377506 @default.
• W2089349496 cites W2006168411 @default.
• W2089349496 cites W2006987944 @default.
• W2089349496 cites W2012024423 @default.
• W2089349496 cites W2028627769 @default.
• W2089349496 cites W2048477643 @default.
• W2089349496 cites W2049723491 @default.
• W2089349496 cites W2055180499 @default.
• W2089349496 cites W2058645214 @default.
• W2089349496 cites W2060824174 @default.
• W2089349496 cites W2073252143 @default.
• W2089349496 cites W2101659058 @default.
• W2089349496 cites W2109197941 @default.
• W2089349496 cites W2112845420 @default.
• W2089349496 cites W2117722883 @default.
• W2089349496 cites W2119312052 @default.
• W2089349496 cites W2139870414 @default.
• W2089349496 cites W2142850084 @default.
• W2089349496 cites W2157352980 @default.
• W2089349496 cites W2158000158 @default.
• W2089349496 cites W2167855391 @default.
• W2089349496 doi "https://doi.org/10.1016/j.jcms.2012.12.006" @default.
• W2089349496 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23375534" @default.
• W2089349496 hasPublicationYear "2013" @default.
• W2089349496 type Work @default.
• W2089349496 sameAs 2089349496 @default.
• W2089349496 citedByCount "20" @default.
• W2089349496 countsByYear W20893494962014 @default.
• W2089349496 countsByYear W20893494962015 @default.
• W2089349496 countsByYear W20893494962016 @default.
• W2089349496 countsByYear W20893494962017 @default.
• W2089349496 countsByYear W20893494962018 @default.
• W2089349496 countsByYear W20893494962019 @default.
• W2089349496 countsByYear W20893494962020 @default.
• W2089349496 countsByYear W20893494962021 @default.
• W2089349496 countsByYear W20893494962022 @default.
• W2089349496 crossrefType "journal-article" @default.
• W2089349496 hasAuthorship W2089349496A5001616605 @default.
• W2089349496 hasAuthorship W2089349496A5010774833 @default.
• W2089349496 hasAuthorship W2089349496A5030811057 @default.
• W2089349496 hasAuthorship W2089349496A5035703944 @default.
• W2089349496 hasAuthorship W2089349496A5057080440 @default.
• W2089349496 hasAuthorship W2089349496A5060991124 @default.
• W2089349496 hasAuthorship W2089349496A5063577202 @default.
• W2089349496 hasAuthorship W2089349496A5063605118 @default.
• W2089349496 hasAuthorship W2089349496A5090518514 @default.
• W2089349496 hasConcept C121608353 @default.
• W2089349496 hasConcept C126322002 @default.
• W2089349496 hasConcept C143998085 @default.
• W2089349496 hasConcept C159654299 @default.
• W2089349496 hasConcept C203014093 @default.
• W2089349496 hasConcept C2778332735 @default.
• W2089349496 hasConcept C2779438470 @default.
• W2089349496 hasConcept C2779998722 @default.
• W2089349496 hasConcept C502942594 @default.
• W2089349496 hasConcept C542903549 @default.
• W2089349496 hasConcept C54355233 @default.
• W2089349496 hasConcept C71924100 @default.
• W2089349496 hasConcept C81885089 @default.
• W2089349496 hasConcept C86803240 @default.
• W2089349496 hasConceptScore W2089349496C121608353 @default.
• W2089349496 hasConceptScore W2089349496C126322002 @default.
• W2089349496 hasConceptScore W2089349496C143998085 @default.
• W2089349496 hasConceptScore W2089349496C159654299 @default.
• W2089349496 hasConceptScore W2089349496C203014093 @default.
• W2089349496 hasConceptScore W2089349496C2778332735 @default.
• W2089349496 hasConceptScore W2089349496C2779438470 @default.
• W2089349496 hasConceptScore W2089349496C2779998722 @default.
• W2089349496 hasConceptScore W2089349496C502942594 @default.
• W2089349496 hasConceptScore W2089349496C542903549 @default.
• W2089349496 hasConceptScore W2089349496C54355233 @default.
• W2089349496 hasConceptScore W2089349496C71924100 @default.
• W2089349496 hasConceptScore W2089349496C81885089 @default.
• W2089349496 hasConceptScore W2089349496C86803240 @default.
• W2089349496 hasIssue "7" @default.
• W2089349496 hasLocation W20893494961 @default.
• W2089349496 hasLocation W20893494962 @default.
• W2089349496 hasOpenAccess W2089349496 @default.
• W2089349496 hasPrimaryLocation W20893494961 @default.
• W2089349496 hasRelatedWork W1858340468 @default.

• next